Navigation Links
Immtech Reports Fiscal First Quarter 2009 Results
Date:8/11/2008

NEW YORK, Aug. 11 /PRNewswire-FirstCall/ -- Immtech Pharmaceuticals, Inc. (Amex: IMM) today announced results for its fiscal quarter ended June 30, 2008.

For the three months ended June 30, 2008, revenues were $1,141,000, as compared to $826,000 for the three months ended June 30, 2007. The increase was primarily attributable to revenues from a research and testing agreement. Loss from operations for the three months ended June 30, 2008 was $1,278,000, as compared to a loss from operations of $2,809,000 for the three months ended June 30, 2007. Net loss attributable to common stockholders for the three months ended June 30, 2008 was $1,383,000, or $0.09 per share, compared to a loss of $2,796,000, or $0.18 per share, in the previous year.

At June 30, 2008, unrestricted cash and cash equivalents were $3,574,000 as compared to $5,996,000 at March 31, 2008. For the same periods, restricted funds on deposit were $2,001,000 and $3,776,000, respectively.

The Company will hold a conference call on Thursday, August 28, 2008 at 2:00 P.M. (EDT) to present an update on the Company's progress and results for fiscal first quarter 2009 results. The User Access Code is # 60063484. Investors and interested parties in the U.S. are invited to join the call by dialing (888) 338-8374 and callers outside the U.S. should call (706) 902-3163. Please call no later than 10 minutes prior to the scheduled start of the call to register. Information to access a recording of the conference call will be available starting on August 28th from the Immtech Pharmaceuticals web site (http://www.immtechpharma.com).

About Immtech Pharmaceuticals, Inc.

Immtech is a pharmaceutical company focused on the development and commercialization of new drugs to treat infectious diseases. Immtech has a well defined, expanding library of compounds targeting Hepatitis C, drug-resistant Gram-positive bacteria, fungal infections and other serious diseases. It is expanding its targeted markets by applying its proprietary pharmaceutical platform to treat a range of disorders. Immtech holds exclusive worldwide licenses to certain patents, patent applications and technology for products derived from its proprietary pharmaceutical platform. For additional information, please visit the Company's website at http://www.immtechpharma.com

"Safe Harbor" Statement under the Private Securities Reform Act of 1995: Statements in this press release regarding Immtech Pharmaceuticals, Inc.'s business which are not historical facts are "forward-looking statements" that involve risks and uncertainties. Actual results could differ materially from these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed under the headings "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Risk Factors" in Immtech's annual report on Form 10-K for the fiscal year ended March 31, 2008 filed with the SEC on June 18, 2008, and in its other SEC filings and include, but are not limited to: (i) Immtech's ability to obtain additional funds; (ii) Immtech's ability to manage its remaining resources; (iii) Immtech's ability to continue as a going concern; (iv) Immtech's ability to retain key personnel; (v) the ability of Immtech's scientists and collaborators to discover new compounds; (vi) the availability of additional research grants; (vii) Immtech's ability to obtain regulatory approval of its drugs candidates; (viii) the success of Immtech's clinical trials; (ix) dependence upon and contractual relationship with partners; (x) Immtech's ability to protect its intellectual property; and (xi) competition and alternative technologies.

In addition, Immtech does not undertake any obligation, and specifically disclaims any obligation, to publicly update or revise forward-looking statements to reflect future events, information or circumstances that arise after the date of this release.

Immtech Pharmaceuticals, Inc.

Selected Financial Information (Unaudited)

(in thousands, except per share amounts)

Three Months Ended

June 30,

2008 2007

REVENUES $ 1,141 $ 826

OPERATING LOSS $ (1,278) $ (2,809)

NET LOSS TO COMMON SHAREHOLDERS $ (1,383) $ (2,796)

NET LOSS PER COMMON SHARE

Basic and diluted $ (0.09) $ (0.18)

AVERAGE COMMON SHARES OUTSTANDING

Basic and diluted 15,846,874 15,370,054


'/>"/>
SOURCE Immtech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Immtech Pharmaceuticals and Beijing Capital Medical University Announce Joint Venture to Provide Contract Research Services in China
2. Immtech Appoints Blythe Weigh as Strategic Advisor
3. Immtech Reports Fiscal Third Quarter 2008 Results
4. Immtech Investor Conference Call Scheduled for February 11, 2008
5. Immtech and BioAlliance Sign Licensing Agreement for Pafuramidine
6. Immtech to Present at The Bank of Montreal Healthcare Conference
7. ULURU Inc. Reports Second Quarter 2008 Financial Results
8. BMP Sunstone Reports Second Quarter 2008 Financial Results
9. MGT Capital Investments Reports Second Quarter 2008 Financial Results and Provides Update on Recent Developments
10. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
11. Pharmos Corporation Reports 2008 Second Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... , March 23, 2017  Northwest Biotherapeutics ... DCVax® personalized immune therapies for solid tumor cancers, ... $7.5 million financing it announced last Friday, March ... to several institutional investors securities totaling 28,843,692 shares, ... share, and 10,000,000 shares of Class C Warrants ...
(Date:3/23/2017)... SEATTLE , March 23, 2017 ... translational development of novel therapies in immuno-oncology, today ... to lead" small molecule compounds that activate interferon ... (RLR) pathways and demonstrate immune-mediated tumor regression in ... in the study who demonstrated complete tumor regression ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... today announced the hire of Dr. Sigmund “Sig” Floyd as Vice President ? ... partnerships and joint development activities. , “Dr. Floyd’s career has spanned 30 years ...
(Date:3/22/2017)... 2017 Good Start Genetics, a leading family ... 130 million covered lives mark through its most recent ... Texas . With newly signed contracts nationally and ... strong payor acceptance based on the quality of its ... counseling, its industry-leading customer care and support and its ...
Breaking Biology Technology:
(Date:3/9/2017)... MOUNTAIN VIEW, Calif. , March 9, ... Simple," and 23andMe , the leading personal genetics ... choices.  Zipongo can now provide customers with personalized nutrition ... goals and biometrics, but also genetic markers impacting how ... Zipongo,s personalized food decision support platform uses biometrics ...
(Date:3/7/2017)...   HireVue , the leading provider of video ... best talent, faster, today announced the additions of ... Diana Kucer as Chief Marketing Officer (CMO). ... poised to drive continued growth in the company,s new ... record bookings in 2017. "Companies worldwide turn ...
(Date:3/2/2017)... -- Summary This report provides all the information ... and activities since 2010. ... Read the full report: http://www.reportlinker.com/p03605615-summary/view-report.html ... provides an in-depth insight into the partnering activity of one ... demand company reports are prepared upon purchase to ensure inclusion ...
Breaking Biology News(10 mins):